Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.42
-0.02 (-0.27%)
At close: Aug 1, 2025, 4:00 PM
7.44
+0.02 (0.27%)
After-hours: Aug 1, 2025, 6:07 PM EDT
Arvinas Revenue
Arvinas had revenue of $188.80M in the quarter ending March 31, 2025, with 646.25% growth. This brings the company's revenue in the last twelve months to $426.90M, up 498.74% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$426.90M
Revenue Growth
+498.74%
P/S Ratio
1.25
Revenue / Employee
$992,791
Employees
430
Market Cap
541.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARVN News
- 2 days ago - Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 24 days ago - Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - GlobeNewsWire
- 7 weeks ago - Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewsWire
- 2 months ago - Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - GlobeNewsWire
- 2 months ago - Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting - GlobeNewsWire
- 2 months ago - Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
- 2 months ago - Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 2 months ago - Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewsWire